Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $74.0 million.

  • Axsome Therapeutics' Accumulated Expenses rose 102.82% to $139.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.5 million, marking a year-over-year increase of 102.82%. This contributed to the annual value of $74.0 million for FY2024, which is 58.31% up from last year.
  • As of FY2024, Axsome Therapeutics' Accumulated Expenses stood at $74.0 million, which was up 58.31% from $46.7 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Accumulated Expenses registered a high of $74.0 million during FY2024, and its lowest value of $26.5 million during FY2022.
  • Its 3-year average for Accumulated Expenses is $49.1 million, with a median of $46.7 million in 2023.
  • Data for Axsome Therapeutics' Accumulated Expenses shows a peak YoY spiked of 75.98% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Accumulated Expenses (Yearly) stood at $26.5 million in 2022, then spiked by 75.98% to $46.7 million in 2023, then skyrocketed by 58.31% to $74.0 million in 2024.